PriceTargets.com logo

Reata Pharmaceuticals - RETA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $162.44
  • Forecasted Upside: -5.75%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 9 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$172.36 As of 09/26/2023 09:00 PM ET
▲ +0.04 (0.02%)
Get New Reata Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RETA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RETA

Analyst Price Target is $162.44
▼ -5.75% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for Reata Pharmaceuticals in the last 3 months. The average price target is $162.44, with a high forecast of $173.00 and a low forecast of $115.00. The average price target represents a -5.75% upside from the last price of $172.36.

This chart shows the closing price for RETA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 12 contributing investment analysts is to hold stock in Reata Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
3/29/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$172.00Low
8/1/2023CitigroupDowngradeBuy ➝ Neutral$127.00 ➝ $172.50Low
8/1/2023BarclaysDowngradeOverweight ➝ Equal Weight$110.00 ➝ $172.00Low
7/31/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$85.00 ➝ $173.00Low
7/31/2023LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$122.00 ➝ $172.50Low
7/28/2023Leerink PartnrsDowngradeOutperform ➝ Market PerformLow
7/28/2023SVB SecuritiesDowngradeOutperform ➝ Market PerformLow
7/28/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$104.00 ➝ $172.50Low
7/28/2023GuggenheimDowngradeBuy ➝ NeutralLow
7/28/2023Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
7/28/2023Stifel NicolausDowngradeBuy ➝ Hold$110.00 ➝ $172.50Low
7/24/2023Cantor FitzgeraldBoost TargetOverweight$110.00 ➝ $145.00Low
7/6/2023TD CowenInitiated CoverageOutperform$140.00Low
6/29/2023LADENBURG THALM/SH SHBoost Target$104.00 ➝ $122.00Low
6/28/2023888Reiterated RatingReiteratesLow
6/28/2023BarclaysBoost Target$98.00 ➝ $110.00Low
6/12/2023SVB LeerinkUpgradeMarket Perform ➝ OutperformLow
6/12/2023SVB SecuritiesUpgradeMarket Perform ➝ Outperform$80.00 ➝ $115.00Low
5/11/2023LADENBURG THALM/SH SHBoost Target$91.00 ➝ $104.00Low
5/10/2023BarclaysBoost Target$90.00 ➝ $98.00Low
5/10/2023Cantor FitzgeraldLower Target$138.00 ➝ $110.00Low
4/13/2023Stifel NicolausBoost TargetBuy$105.00 ➝ $115.00Low
3/27/2023Cantor FitzgeraldBoost TargetOverweight$121.00 ➝ $138.00Low
3/1/2023SVB SecuritiesBoost Target$35.00 ➝ $75.00N/A
3/1/2023Stifel NicolausBoost Target$75.00 ➝ $105.00N/A
3/1/2023Robert W. BairdBoost TargetNeutral$40.00 ➝ $85.00N/A
3/1/2023Cantor FitzgeraldBoost TargetOverweight$61.00 ➝ $121.00N/A
3/1/2023CitigroupBoost TargetBuy$53.00 ➝ $120.00N/A
3/1/2023BarclaysBoost TargetOverweight$50.00 ➝ $90.00N/A
2/24/2023The Goldman Sachs GroupBoost TargetBuy$115.00 ➝ $117.00Low
11/28/2022The Goldman Sachs GroupBoost TargetBuy$86.00 ➝ $115.00Low
11/15/2022Robert W. BairdBoost Target$40.00Low
11/9/2022The Goldman Sachs GroupBoost TargetBuy$76.00 ➝ $86.00Low
11/9/2022CitigroupBoost TargetBuy$51.00 ➝ $53.00Low
11/9/2022BarclaysBoost TargetOverweight$43.00 ➝ $50.00N/A
10/19/2022GuggenheimInitiated CoverageBuy$75.00Low
10/11/2022CitigroupBoost Target$40.00 ➝ $48.00Low
8/9/2022Robert W. BairdLower TargetNeutral$37.00 ➝ $27.00Low
5/27/2022CitigroupBoost TargetBuy$43.00 ➝ $46.00High
5/24/2022The Goldman Sachs GroupLower TargetBuy$93.00 ➝ $73.00Medium
5/11/2022LADENBURG THALM/SH SHLower Target$75.00 ➝ $67.00Medium
3/24/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$34.00 ➝ $91.00High
3/1/2022The Goldman Sachs GroupLower TargetNeutral$39.00 ➝ $34.00Medium
12/9/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$39.00High
12/9/2021BarclaysLower TargetOverweight ➝ Overweight$180.00 ➝ $43.00High
12/9/2021Robert W. BairdDowngradeOutperform ➝ Neutral$110.00 ➝ $37.00High
12/9/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$282.00 ➝ $35.00High
12/7/2021Cantor FitzgeraldLower TargetOverweight ➝ Overweight$230.00 ➝ $112.00High
12/6/2021Robert W. BairdLower TargetOutperform$212.00 ➝ $110.00High
5/24/2021The Goldman Sachs GroupInitiated CoverageBuy$236.00High
5/20/2021CitigroupBoost TargetPositive ➝ Buy$234.00 ➝ $244.00High
4/26/2021BarclaysInitiated CoverageOverweight$155.00High
11/25/2020Smith Barney CitigroupLower Target$260.00 ➝ $234.00Low
11/10/2020Cantor FitzgeraldBoost Target$169.00 ➝ $220.00High
11/10/2020Smith Barney CitigroupBoost Target$244.00 ➝ $260.00High
8/11/2020Cantor FitzgeraldLower Target$275.00 ➝ $169.00High
8/11/2020CitigroupLower TargetBuy$254.00 ➝ $244.00High
8/10/2020Stifel NicolausLower TargetBuy$280.00 ➝ $225.00Low
6/16/2020BTIG ResearchInitiated CoverageBuy$237.00Low
6/12/2020Robert W. BairdReiterated RatingBuy$268.00Low
5/18/2020Cantor FitzgeraldBoost TargetOverweight$270.00 ➝ $275.00Medium
4/17/2020Jefferies Financial GroupBoost TargetBuy$335.00 ➝ $348.00Low
3/31/2020Stifel NicolausLower TargetBuy$362.00 ➝ $315.00High
3/31/2020Robert W. BairdLower TargetOutperform$283.00 ➝ $268.00High
3/31/2020CitigroupLower TargetBuy$328.00 ➝ $254.00High
2/20/2020Stifel NicolausBoost TargetBuy$305.00 ➝ $362.00Medium
2/20/2020Robert W. BairdReiterated RatingOutperform$245.00 ➝ $283.00Low
2/20/2020Cantor FitzgeraldReiterated RatingOverweight$314.00 ➝ $320.00High
2/18/2020Jefferies Financial GroupReiterated RatingBuy$308.00 ➝ $333.00Medium
11/27/2019Cantor FitzgeraldBoost Target$250.00 ➝ $314.00Low
11/20/2019Cantor FitzgeraldReiterated RatingOverweight$250.00 ➝ $314.00Medium
11/14/2019Stifel NicolausReiterated RatingPositive ➝ Buy$210.00 ➝ $305.00Low
11/13/2019National SecuritiesDowngradeBuy ➝ NeutralMedium
11/12/2019CitigroupBoost TargetBuy$241.00 ➝ $328.00Medium
11/12/2019Robert W. BairdBoost TargetOutperform ➝ Positive$162.00 ➝ $245.00High
11/4/2019Cantor FitzgeraldBoost TargetOverweight$180.00 ➝ $250.00Medium
10/16/2019LADENBURG THALM/SH SHReiterated RatingBuy ➝ Positive$133.00 ➝ $239.00High
10/16/2019Stifel NicolausBoost TargetBuy$135.00 ➝ $210.00High
10/15/2019SVB LeerinkSet TargetBuy$230.00Medium
10/15/2019CitigroupBoost TargetBuy$194.00 ➝ $241.00High
10/15/2019Jefferies Financial GroupBoost TargetPositive ➝ Buy$128.00 ➝ $254.00High
10/15/2019Robert W. BairdReiterated RatingOutperform$105.00 ➝ $162.00High
10/15/2019Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$125.00 ➝ $180.00High
10/14/2019SVB LeerinkBoost TargetOutperform$139.00 ➝ $180.00High
9/26/2019CitigroupReiterated RatingBuyHigh
9/26/2019National SecuritiesInitiated CoverageBuy$130.00Medium
8/8/2019CitigroupBoost TargetBuy$190.00 ➝ $194.00Medium
5/31/2019CitigroupBoost TargetBuy$185.00 ➝ $190.00Low
(Data available from 4/28/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Reata Pharmaceuticals logo
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Read More

Today's Range

Now: $172.36
Low: $172.32
High: $172.46

50 Day Range

MA: $171.30
Low: $168.70
High: $172.36

52 Week Range

Now: $172.36
Low: $21.83
High: $172.46

Volume

1,988,500 shs

Average Volume

1,091,032 shs

Market Capitalization

$6.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Reata Pharmaceuticals?

The following equities research analysts have issued research reports on Reata Pharmaceuticals in the last year: 888 Holdings plc, Barclays PLC, Cantor Fitzgerald, Citigroup Inc., Guggenheim, Jefferies Financial Group Inc., LADENBURG THALM/SH SH, Leerink Partnrs, Robert W. Baird, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, SVB Securities, and TD Cowen.
View the latest analyst ratings for RETA.

What is the current price target for Reata Pharmaceuticals?

9 Wall Street analysts have set twelve-month price targets for Reata Pharmaceuticals in the last year. Their average twelve-month price target is $162.44, suggesting a possible downside of 5.8%. Robert W. Baird has the highest price target set, predicting RETA will reach $173.00 in the next twelve months. SVB Securities has the lowest price target set, forecasting a price of $115.00 for Reata Pharmaceuticals in the next year.
View the latest price targets for RETA.

What is the current consensus analyst rating for Reata Pharmaceuticals?

Reata Pharmaceuticals currently has 9 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RETA, but not buy more shares or sell existing shares.
View the latest ratings for RETA.

What other companies compete with Reata Pharmaceuticals?

Other companies that are similar to Reata Pharmaceuticals include Elanco Animal Health, Cytokinetics, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Viking Therapeutics. Learn More about companies similar to Reata Pharmaceuticals.

How do I contact Reata Pharmaceuticals' investor relations team?

Reata Pharmaceuticals' physical mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company's listed phone number is (972) 865-2219 and its investor relations email address is [email protected]. The official website for Reata Pharmaceuticals is www.reatapharma.com. Learn More about contacing Reata Pharmaceuticals investor relations.